1. Home
  2. ZCMD vs PFSA Comparison

ZCMD vs PFSA Comparison

Compare ZCMD & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

HOLD

Current Price

$0.91

Market Cap

2.0M

Sector

Real Estate

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$3.06

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
PFSA
Founded
2012
2009
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ZCMD
PFSA
Price
$0.91
$3.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.1M
2.2M
Earning Date
04-28-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.05
52 Week High
$11.96
$28.32

Technical Indicators

Market Signals
Indicator
ZCMD
PFSA
Relative Strength Index (RSI) 46.02 49.73
Support Level $0.54 $0.42
Resistance Level $0.97 $28.32
Average True Range (ATR) 0.10 2.92
MACD -0.00 -0.35
Stochastic Oscillator 47.17 11.83

Price Performance

Historical Comparison
ZCMD
PFSA

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: